3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
BRAF V600E Mutation
1
Interventions
venetoclax
190
Azacitidine
162
Cytarabine
127
fludarabine
97
Cyclophosphamide
75
Specimen Handling
68
fludarabine phosphate
56
Daunorubicin
53
Biopsy
49
Decitabine
48
Whole-Body Irradiation
42
Mycophenolic Acid
40
Idarubicin
40
Busulfan
37
Injections
36
Tacrolimus
35
Granulocyte Colony-Stimulating Factor
35
Melphalan
32
Stem Cell Transplantation
30
gilteritinib
25
Filgrastim
25
CPX-351
25
decitabine and cedazuridine drug combination
23
Peripheral Blood Stem Cell Transplantation
22
Etoposide
20
ivosidenib
19
Mitoxantrone
19
Cladribine
19
Thiotepa
17
Sirolimus
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
Cobicistat
×
1 year
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA